PMID- 30191811
OWN - NLM
STAT- MEDLINE
DCOM- 20191021
LR  - 20191022
IS  - 2452-3186 (Electronic)
IS  - 2452-3186 (Linking)
VI  - 66
IP  - 3
DP  - 2018 Sep
TI  - Acute polyradiculopathy secondary to idelalisib in Relapsed Classical Hodgkin's 
      lymphoma.
PG  - 87-89
LID - S2452-3186(18)30025-4 [pii]
LID - 10.1016/j.retram.2018.04.004 [doi]
AB  - Patients with relapsed or refractory Hodgkin's lymphoma are likely incurable with 
      standard treatment. Idelalisib, a delta-isoform specific 
      Phosphatidyl-inositol-3-kinase (PI3K) inhibitor has shown its efficacy in other 
      hematopoietic B malignancies. We report the case of a 51-years old patient with 
      relapsed and refractory Hodgkin's Lymphoma receiving idelalisib after several 
      regimens of chemotherapy. He achieved a good partial response for several months, 
      unfortunately, idelalisib had to be stopped because of the onset of a severe 
      polyradiculoneuritis attributed to this treatment. We assume here that the 
      polyradiculoneuritis could be caused by T cell mediated autoimmunity to myelin 
      proteins. To our knowledge, this adverse event has never been described so far 
      with idelalisib.
CI  - Copyright (c) 2018 Elsevier Masson SAS. All rights reserved.
FAU - Barbieux, S
AU  - Barbieux S
AD  - Hematology Department, Huriez Hospital, University of Lille, Lille, France.
FAU - Boyle, E M
AU  - Boyle EM
AD  - Hematology Department, Huriez Hospital, University of Lille, Lille, France.
FAU - Baillet, C
AU  - Baillet C
AD  - Nuclear Medicine Department, Huriez Hospital, University of Lille, Lille, France.
FAU - Demarquette, H
AU  - Demarquette H
AD  - Hematology Department, Huriez Hospital, University of Lille, Lille, France.
FAU - Vermersch, P
AU  - Vermersch P
AD  - Univ Lille, CHU Lille, LIRIC-INSERM U995, FHU-Imminent, Lille, France.
FAU - Morschhauser, F
AU  - Morschhauser F
AD  - Hematology Department, Huriez Hospital, University of Lille, Lille, France; 
      Groupe de Recherche sur les Formes Injectables et les Technologies Associees, 
      Lille, France.
FAU - Herbaux, C
AU  - Herbaux C
AD  - Hematology Department, Huriez Hospital, University of Lille, Lille, France. 
      Electronic address: charles.herbaux@chru-lille.fr.
LA  - eng
PT  - Case Reports
PT  - Journal Article
DEP - 20180704
PL  - France
TA  - Curr Res Transl Med
JT  - Current research in translational medicine
JID - 101681234
RN  - 0 (Purines)
RN  - 0 (Quinazolinones)
RN  - YG57I8T5M0 (idelalisib)
SB  - IM
MH  - Acute Disease
MH  - Adult
MH  - Hodgkin Disease/*drug therapy/pathology
MH  - Humans
MH  - Male
MH  - Polyradiculopathy/*chemically induced/diagnosis
MH  - Purines/*adverse effects/therapeutic use
MH  - Quinazolinones/*adverse effects/therapeutic use
MH  - Recurrence
OTO - NOTNLM
OT  - Hodgkin's lymphoma
OT  - Idelalisib
OT  - Polyradiculopathy
EDAT- 2018/09/08 06:00
MHDA- 2019/10/23 06:00
CRDT- 2018/09/08 06:00
PHST- 2018/03/05 00:00 [received]
PHST- 2018/04/11 00:00 [revised]
PHST- 2018/04/15 00:00 [accepted]
PHST- 2018/09/08 06:00 [pubmed]
PHST- 2019/10/23 06:00 [medline]
PHST- 2018/09/08 06:00 [entrez]
AID - S2452-3186(18)30025-4 [pii]
AID - 10.1016/j.retram.2018.04.004 [doi]
PST - ppublish
SO  - Curr Res Transl Med. 2018 Sep;66(3):87-89. doi: 10.1016/j.retram.2018.04.004. 
      Epub 2018 Jul 4.